Key points from article :
Longevity entrepreneur Bryan Johnson has sparked debate after announcing that he had "cloned" himself as part of his quest to develop future treatments for ageing and disease. Johnson said the project involved reprogramming cells taken from his own blood into a youthful, stem cell-like state, describing the resulting laboratory-grown cells as a "newborn" version of himself.
Johnson believes the cells could one day be used to test new therapies, grow replacement organs and repair damaged tissues. However, scientists have stressed that this does not represent a human clone in the conventional sense. Instead, the technique produces induced pluripotent stem cells (iPSCs), a well-established technology that allows adult cells to be reset into an embryonic-like state capable of developing into many different cell types.
While iPSC research has already entered clinical trials for conditions including Parkinson's disease and certain eye disorders, growing fully functional replacement organs remains a major scientific challenge. Experts say Johnson's announcement highlights the promise of regenerative medicine but caution that many of the applications he describes are still years away and have yet to be demonstrated in clinical practice.
The announcement has also reignited ethical discussions about how emerging stem cell technologies should be described and regulated. Researchers emphasise that although regenerative medicine is advancing rapidly, claims about "cloning" should be interpreted carefully to avoid overstating what current science can achieve.
